利用远程医疗改善心力衰竭再入院的随机对照试验综述:现实的方法可以弥合翻译鸿沟吗?

IF 2.3 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS
M. Gonzalez Garcia, Farhad Fatehi, N. Bashi, M. Varnfield, P. Iyngkaran, A. Driscoll, C. Neil, D. Hare, B. Oldenburg
{"title":"利用远程医疗改善心力衰竭再入院的随机对照试验综述:现实的方法可以弥合翻译鸿沟吗?","authors":"M. Gonzalez Garcia, Farhad Fatehi, N. Bashi, M. Varnfield, P. Iyngkaran, A. Driscoll, C. Neil, D. Hare, B. Oldenburg","doi":"10.1177/1179546819861396","DOIUrl":null,"url":null,"abstract":"Background: Telemedicine and digital health technologies hold great promise for improving clinical care of heart failure. However, inconsistent and contradictory findings from randomized controlled trials have so far discouraged widespread adoption of digital health in routine clinical practice. We undertook this review study to summarize the study outcomes of the use of exploring the evidence for telemedicine in the clinical care of patients with heart failure and readmissions. Methods: We inspected the references of guidelines and searched PubMed for randomized controlled trials published over the past 10 years on the use of telemedicine for reducing readmission in heart failure. We utilized a modified realist review approach to identify the underlying contextual mechanisms for the intervention(s) in each randomized controlled trial, evaluating outcomes of the intervention and understanding how and under what conditions they worked. To provide uniformity, all extracted data were synthesized using adapted domains from the taxonomy for disease management created by the Disease Management Taxonomy Writing Group. Results: A total of 12 papers were eligible, 6 of them supporting and 6 others undermining the use of telemedicine for improving heart failure readmission. In general terms, those studies not supporting the use of telemedicine were multicentre, publicly funded, with large amount of participants, and long duration. The patients had also better rates of treatment with angiotensin-converting enzyme inhibitors/angiotensin II receptor blocker and beta-blockers, and telemonitoring and automatic transmission of vital signs were less utilized, in comparison with the studies in which telemedicine use was supported. The analysis of the environment, intensity, content of interventions, method of communication, quality of the underlying model of care and the ability, capability, and interest from health workers can help us to envisage probabilities of success of telemedicine use. Conclusions: A realist lens may aid to understand whom and in which circumstances the use of telemedicine can add any substantial value to traditional models of care. Wider outcome criteria beyond major adverse cardiovascular events, for example, cost efficacy, should also be considered as appropriate for effecting guidelines on care delivery when robust prognostic therapeutics already exist.","PeriodicalId":10419,"journal":{"name":"Clinical Medicine Insights. Cardiology","volume":"79 1","pages":""},"PeriodicalIF":2.3000,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"12","resultStr":"{\"title\":\"A Review of Randomized Controlled Trials Utilizing Telemedicine for Improving Heart Failure Readmission: Can a Realist Approach Bridge the Translational Divide?\",\"authors\":\"M. Gonzalez Garcia, Farhad Fatehi, N. Bashi, M. Varnfield, P. Iyngkaran, A. Driscoll, C. Neil, D. Hare, B. Oldenburg\",\"doi\":\"10.1177/1179546819861396\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: Telemedicine and digital health technologies hold great promise for improving clinical care of heart failure. However, inconsistent and contradictory findings from randomized controlled trials have so far discouraged widespread adoption of digital health in routine clinical practice. We undertook this review study to summarize the study outcomes of the use of exploring the evidence for telemedicine in the clinical care of patients with heart failure and readmissions. Methods: We inspected the references of guidelines and searched PubMed for randomized controlled trials published over the past 10 years on the use of telemedicine for reducing readmission in heart failure. We utilized a modified realist review approach to identify the underlying contextual mechanisms for the intervention(s) in each randomized controlled trial, evaluating outcomes of the intervention and understanding how and under what conditions they worked. To provide uniformity, all extracted data were synthesized using adapted domains from the taxonomy for disease management created by the Disease Management Taxonomy Writing Group. Results: A total of 12 papers were eligible, 6 of them supporting and 6 others undermining the use of telemedicine for improving heart failure readmission. In general terms, those studies not supporting the use of telemedicine were multicentre, publicly funded, with large amount of participants, and long duration. The patients had also better rates of treatment with angiotensin-converting enzyme inhibitors/angiotensin II receptor blocker and beta-blockers, and telemonitoring and automatic transmission of vital signs were less utilized, in comparison with the studies in which telemedicine use was supported. The analysis of the environment, intensity, content of interventions, method of communication, quality of the underlying model of care and the ability, capability, and interest from health workers can help us to envisage probabilities of success of telemedicine use. Conclusions: A realist lens may aid to understand whom and in which circumstances the use of telemedicine can add any substantial value to traditional models of care. Wider outcome criteria beyond major adverse cardiovascular events, for example, cost efficacy, should also be considered as appropriate for effecting guidelines on care delivery when robust prognostic therapeutics already exist.\",\"PeriodicalId\":10419,\"journal\":{\"name\":\"Clinical Medicine Insights. Cardiology\",\"volume\":\"79 1\",\"pages\":\"\"},\"PeriodicalIF\":2.3000,\"publicationDate\":\"2019-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"12\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Medicine Insights. Cardiology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1177/1179546819861396\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Medicine Insights. Cardiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/1179546819861396","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 12

摘要

背景:远程医疗和数字健康技术对改善心力衰竭的临床护理具有很大的希望。然而,随机对照试验中不一致和相互矛盾的发现迄今为止阻碍了数字健康在常规临床实践中的广泛采用。我们进行了这项回顾性研究,以总结在心力衰竭和再入院患者的临床护理中使用远程医疗的研究结果。方法:我们查阅了指南的参考文献,并在PubMed检索了过去10年发表的关于使用远程医疗减少心力衰竭再入院的随机对照试验。我们利用一种改良的现实主义回顾方法来确定每个随机对照试验中干预的潜在背景机制,评估干预的结果,并了解它们是如何以及在什么条件下起作用的。为了提供一致性,所有提取的数据都使用疾病管理分类编写组创建的疾病管理分类中的适应域进行合成。结果:12篇论文入选,支持远程医疗改善心力衰竭再入院6篇,反对远程医疗改善心力衰竭再入院6篇。一般来说,那些不支持使用远程医疗的研究是多中心的、公共资助的、参与人数多、持续时间长。与支持使用远程医疗的研究相比,患者使用血管紧张素转换酶抑制剂/血管紧张素II受体阻滞剂和β受体阻滞剂的治疗率也更高,并且远程监测和生命体征自动传输的使用较少。对环境、强度、干预措施的内容、沟通方法、基本护理模式的质量以及卫生工作者的能力、能力和兴趣的分析可以帮助我们设想远程医疗使用成功的可能性。结论:现实的视角可能有助于理解远程医疗的使用可以为传统的医疗模式增加任何实质性的价值。除了主要心血管不良事件之外,更广泛的结果标准,例如,成本效益,也应考虑在已经存在可靠的预后治疗方法的情况下,适用于影响护理提供指南。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
A Review of Randomized Controlled Trials Utilizing Telemedicine for Improving Heart Failure Readmission: Can a Realist Approach Bridge the Translational Divide?
Background: Telemedicine and digital health technologies hold great promise for improving clinical care of heart failure. However, inconsistent and contradictory findings from randomized controlled trials have so far discouraged widespread adoption of digital health in routine clinical practice. We undertook this review study to summarize the study outcomes of the use of exploring the evidence for telemedicine in the clinical care of patients with heart failure and readmissions. Methods: We inspected the references of guidelines and searched PubMed for randomized controlled trials published over the past 10 years on the use of telemedicine for reducing readmission in heart failure. We utilized a modified realist review approach to identify the underlying contextual mechanisms for the intervention(s) in each randomized controlled trial, evaluating outcomes of the intervention and understanding how and under what conditions they worked. To provide uniformity, all extracted data were synthesized using adapted domains from the taxonomy for disease management created by the Disease Management Taxonomy Writing Group. Results: A total of 12 papers were eligible, 6 of them supporting and 6 others undermining the use of telemedicine for improving heart failure readmission. In general terms, those studies not supporting the use of telemedicine were multicentre, publicly funded, with large amount of participants, and long duration. The patients had also better rates of treatment with angiotensin-converting enzyme inhibitors/angiotensin II receptor blocker and beta-blockers, and telemonitoring and automatic transmission of vital signs were less utilized, in comparison with the studies in which telemedicine use was supported. The analysis of the environment, intensity, content of interventions, method of communication, quality of the underlying model of care and the ability, capability, and interest from health workers can help us to envisage probabilities of success of telemedicine use. Conclusions: A realist lens may aid to understand whom and in which circumstances the use of telemedicine can add any substantial value to traditional models of care. Wider outcome criteria beyond major adverse cardiovascular events, for example, cost efficacy, should also be considered as appropriate for effecting guidelines on care delivery when robust prognostic therapeutics already exist.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Clinical Medicine Insights. Cardiology
Clinical Medicine Insights. Cardiology CARDIAC & CARDIOVASCULAR SYSTEMS-
CiteScore
5.20
自引率
3.30%
发文量
16
审稿时长
8 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信